Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?

被引：0
|
作者：
Kubilay Karaboyun
Eyyup Cavdar
Yakup Irıagac
Abdussamet Celebı
Tanju Kapagan
Ilkay Gulturk
Ozden Demır
Okan Avcı
Erdogan Selcuk Seber
机构：
[1] Tekirdag Namik Kemal University,Department of Medical Oncology, School of Medicine
[2] Marmara University,Department of Medical Oncology, School of Medicine
[3] Basaksehir Cam and Sakura City Hospital,Department of Medical Oncology
[4] Bakirkoy Dr. Sadi Konuk Training and Research Hospital,Department of Medical Oncology
[5] Ondokuz Mayıs University,Department of Medical Oncology, School of Medicine
来源：
Supportive Care in Cancer | 2023年 / 31卷
关键词：
Urinary Incontinence; Early breast cancer; Adjuvant hormone therapy; Tamoxifen; Aromatase inhibitor; ICIQ-UI SF;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?
    Karaboyun, Kubilay
    Cavdar, Eyyup
    Iriagac, Yakup
    Celebi, Abdussamet
    Kapagan, Tanju
    Gulturk, Ilkay
    Demir, Ozden
    Avci, Okan
    Seber, Erdogan Selcuk
    SUPPORTIVE CARE IN CANCER, 2023, 31 (06)
  • [2] Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
    Holm Eggemann
    Atanas Ignatov
    Bobbie J. Smith
    Udo Altmann
    Gunter von Minckwitz
    Freidrich W. Röhl
    Mark Jahn
    Serban-Dan Costa
    Breast Cancer Research and Treatment, 2013, 137 : 465 - 470
  • [3] Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
    Eggemann, Holm
    Ignatov, Atanas
    Smith, Bobbie J.
    Altmann, Udo
    von Minckwitz, Gunter
    Roehl, Freidrich W.
    Jahn, Mark
    Costa, Serban-Dan
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (02) : 465 - 470
  • [4] Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer
    van de Velde, C. J. H.
    Verma, S.
    van Nes, J. G. H.
    Masterman, C.
    Pritchard, K. I.
    CANCER TREATMENT REVIEWS, 2010, 36 (01) : 54 - 62
  • [5] Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer
    Perez, E. A.
    ANNALS OF ONCOLOGY, 2007, 18 : 26 - 35
  • [6] Aromatase inhibitors as adjuvant therapy for breast cancer
    Maass, N
    Jonat, W
    GYNAKOLOGE, 2003, 36 (02): : 103 - 109
  • [7] Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer
    Montemurro, Filippo
    Aglietta, Massimo
    Del Mastro, Lucia
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) : 2566 - 2567
  • [8] Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: Aromatase inhibitors versus tamoxifen
    Carpenter, R.
    EJSO, 2008, 34 (07): : 746 - 755
  • [9] A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI
    A. Lintermans
    K. Van Asten
    H. Wildiers
    A. Laenen
    R. Paridaens
    C. Weltens
    J. Verhaeghe
    D. Vanderschueren
    A. Smeets
    E. Van Limbergen
    K. Leunen
    M. R. Christiaens
    P. Neven
    Breast Cancer Research and Treatment, 2014, 146 : 109 - 116
  • [10] A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI
    Lintermans, A.
    Van Asten, K.
    Wildiers, H.
    Laenen, A.
    Paridaens, R.
    Weltens, C.
    Verhaeghe, J.
    Vanderschueren, D.
    Smeets, A.
    Van Limbergen, E.
    Leunen, K.
    Christiaens, M. R.
    Neven, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 146 (01) : 109 - 116
12345